Venetoclax (ABT-199, Venclexta), a first-in-class BCL-2 inhibitor, has transformed the treatment of hematologic cancers, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and acute myeloid leukemia (AML) [1]. This evidence concerns the gene BCL2 and acute myeloid leukemia.